David Rozema

Dr. David Rozema holds a Bachelor’s degree in chemistry for Calvin College and a PhD in chemistry from the University of Wisconsin. He has worked more than 18 years on the in vivo delivery of nucleic acids. At MirusBio, he developed techniques to facilitate intracellular delivery, which led to the discovery of polymer-based delivery vehicles termed dynamic polyconjugates (DPCs). DPC technology was acquired by Roche Pharmaceuticals and then Arrowhead where David led the discovery and development efforts for clinical programs based upon DPC technology. David has more than 40 issued US patents, been primary investigator on 3 NIH-funded SBIR grants and serves on the NIH Bioengineering Sciences and Technologies SBIR grant committee.